



ARTICLE

Open Access

LncRNA *DANCR* upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA

Jianming Tang¹, Guangsheng Zhong², Haibo Zhang¹, Bo Yu³, Fangqiang Wei⁴, Liming Luo¹, Yao kang⁵, Jianhui Wu⁶, Jiayang Jiang⁷, Yucheng Li¹, Shuqiang Wu¹, Yongshi Jia¹, Xiaodong Liang¹ and Aihong Bi¹

Abstract

Conventional therapies and novel molecular targeted therapies against breast cancer have gained great advances over the past two decades. However, poor prognosis and low survival rate are far from expectation for improvement, particularly in patients with triple negative breast cancer (TNBC). Here, we found that lncRNA *DANCR* was significantly overregulated in TNBC tissues and cell lines compared with normal breast tissues or other type of breast cancer. Knockdown of *DANCR* suppressed TNBC proliferation both in vitro and in vivo. Further study of underlying mechanisms demonstrated that *DANCR* bound with RXRA and increased its serine 49/78 phosphorylation via GSK3 β , resulting in activating PIK3CA transcription, and subsequently enhanced PI3K/AKT signaling and TNBC tumorigenesis. Taken together, Our findings identified *DANCR* as a pro-oncogene and uncovered a new working pattern of lncRNA to mediate TNBC tumorigenesis, which may be a potential therapeutic target for improving treatment of TNBC.

Introduction

Breast cancer is the most prevalent malignant tumor in women, and the efficacy of currently available therapies seems far from satisfactory, which severely threatens the health of females from all over the world^{1,2}. Generally, breast cancer can be classified into four subtypes, including luminal type A, luminal type B, human epidermal growth factor receptor-2 (HER2) positive type, and triple-negative breast cancer (TNBC) type³. TNBC demonstrates a lack of ER, PR, and HER2 expression by immunohistochemical results, and acts as a highly

invasive subtype comprising about 20% of all breast cancer patients^{4,5}. Furthermore, TNBC can exhibit high invasiveness, metastasis, high recurrence risk, and mortality rates, resulting in poor prognosis⁶. The lack of molecular targeted therapies and the poor survival of TNBC patients have fostered great endeavors to discover precise molecular targets for clinical treatment strategies. A growing body of evidence suggests that long non-coding RNAs (lncRNAs) are involved in TNBC progression through regulating tumor-related gene expression⁷⁻⁹. However, the precise molecular mechanisms by which lncRNA mediates TNBC progression remain unclear.

Differentiation antagonizing non-protein coding RNA (*DANCR*), an lncRNA encoded on human chromosome 4q12, has been identified as an oncogene in multiple malignant tumors, including colon cancer¹⁰, esophageal cancer¹¹, hepatocellular carcinoma¹², osteosarcoma¹³, TNBC¹⁴. *DANCR* was previously demonstrated to contribute to suppression of cell differentiation due to acting as a negative regulator^{15,16}. Recent studies demonstrated

Correspondence: Jianming Tang (tangjianming@sjtu.edu.cn) or

Xiaodong Liang (lxdtctopone@sina.com) or Aihong Bi (150523@163.com)

¹Department of Radiation Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China

²Department of Thyroid and Breast Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China

Full list of author information is available at the end of the article.

These authors contributed equally: Jianming Tang, Guangsheng Zhong, Haibo Zhang, Bo Yu

Edited by B. Rotblat

© The Author(s) 2018



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

that *DANCR* directly interacts with miR-758-3p¹⁷ and miR-577¹⁸ in non-small cell lung cancer and colorectal cancer, respectively. *DANCR* represses the expression of TIMP2/3 through physical binding with EZH2 in prostate cancer¹⁹. *DANCR* is also shown as a direct target of MYC in cancer²⁰. Furthermore, *DANCR* expression is correlated with survival and/or prognosis of patients with hepatocellular carcinoma¹², gastric cancer²¹, and colorectal cancer¹⁰. However, **due to the molecular and phenotypic heterogeneity within and between different tumor types, mechanism explorations are required to elucidate the precise biological behaviour of *DANCR* in tumors, especially TNBC.**

Here, we showed that *DANCR* is more highly expressed in TNBC compared with that in normal breast tissues, which exhibits poor prognosis. *DANCR* promoted proliferation and tumorigenesis in TNBC through activating ser49/78 phosphorylation of RXRA, and thus promoting PIK3CA expression. We also showed that signaling axis *DANCR*-RXRA-PI3K/AKT plays important roles in TNBC proliferation and tumorigenesis in vitro and vivo, respectively. In conclusion, the present study elucidated the function of *DANCR* in TNBC and might provide a novel of signaling pathway in the treatment of TNBC.

Materials and methods

Clinical samples

Between August 2013 and August 2015, clinical specimens containing breast cancer tissues including 60 triple-negative (TNBC) type, 15 HER2 type, 15 Luminal A type, and 15 Luminal B type, and 10 normal breast tissues were obtained from department of Breast Surgery in Meizhou People's Hospital. All these patients had not received chemotherapy and radiotherapy before the operation and all clinical samples were confirmed by pathology. This study protocol approval from the Research Ethics Committee of the Meizhou People's Hospital, and written informed consent from each participant were obtained.

Cell lines

BT549, MCF7, T47D, MDA-MB-231, MDA-MB-453, and MDA-MB-468 cells were purchased from Cell Bank of the Chinese Scientific Academy (Shanghai, China), and were cultured in Dulbecco's modified Eagle's medium (DMEM) (Hyclone, Life Technologies, CA) with 10% fetal bovine serum (Hyclone, Life Technologies, CA). MCF10A was also from Cell Bank of the Chinese Scientific Academy (Shanghai, China), and was cultured in DMEM/F12 (Hyclone, Life Technologies, CA) supplemented with 5% horse serum (Invitrogen, Carlsbad, CA), 20 ng/ml hEGF (Sigma-Aldrich), 0.5 µg/ml hydrocortisone (Sigma-Aldrich), 100 ng/ml cholera toxin (Sigma-Aldrich), 10 µg/ml insulin (Sigma-Aldrich), and 100 U/ml penicillin-streptomycin (Sigma-Aldrich). BT549, MCF7, T47D,

MDA-MB-231, MDA-MB-453, MDA-MB-468, and MCF10A were recently authenticated through using STR DNA fingerprinting from Shanghai Biowing Applied Biotechnology Co., Ltd. Moreover, by using LookOut Mycoplasma PCR Detection kit (Sigma-Aldrich), we detected the mycoplasma infection.

RNA extraction and quantitative RT-PCR

Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and extracted according to the manufacturers' protocol (Sigma-Aldrich). Reverse transcription (RT) was performed using the M-MLV Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative RT-PCR was performed by means of Power qPCR Premix (SYBR Green) (Shanghai Genaray Biotech CoCo., Ltd). GAPDH was used as a control. Primers are contained in Supplementary Table S1.

Western blot analysis

Western blot was performed as we previously described²². The specific antibodies for WB as follows: anti-RXRA (21218-1-AP, 1:1000, Proteintech), Phospho-RXRA (PA5-64630, 1:1000, Invitrogen), GSK3β (ab65740, 1:1000, Abcam), Akt (#4685S, 1:1000, Cell Signaling Technology), Phospho-Akt (#4060S, 1:1000, Cell Signaling Technology), PIK3CA (MA5-17149, 1:1000, Thermo Fisher), GAPDH (#5174S, 1:1000, Cell Signaling Technology).

ChIP-qPCR

ChIP assay was performed using EZ-Magna ChIP™ A/G Chromatin Immunoprecipitation Kit (Millipore-17-408) referring to the manufacturer's protocol.

Input genomic DNA and the purified immunoprecipitated DNA were used for qRT-PCR. Primers are contained in Supplementary Table 1.

Luciferase promoter assay

pGL3-PIK3CA promoter wild or mutant type of the RXRA binding was performed co-transfection with or without RXRA using Lipofectamine RNAiMAX Reagent (Thermo Fisher) referring to the manufacturer's protocol. pRL Renilla luciferase control reporter vector (Promega) was presented as a control. A dual-luciferase assay was analyzed 48 h after co-transfection using the Promega E1960 Dual-Luciferase® Reporter System in accordance with the manufacturer recommendation.

RNA immunoprecipitation (RIP) and RNA pull-down assays

The EZ-Magna RIP Kit (17-701, Millipore) was used for RIP assay with 10 µg anti-RXRA (21218-1-AP, Proteintech) referring to the manufacturer recommendation. The purified immunoprecipitated RNA and input genomic RNA were detected by quantitative RT-PCR. Biotin-labeled RNA was transcribed with Biotin RNA Labeling

Mix (Roche 11685597910) and T7 RNA polymerase (Roche 10881775001), mixed with DNase I recombinant (Roche 04716728001), and purified with RNeasy Mini Kit (Qiagen 74904). Cell nuclear proteins were extracted using the pierce 78833 NE-PER (R) Nuclear and Cytoplasmic Extraction Reagents. Cell nuclear extract was mixed with Biotin-labeled RNA. Washed streptavidin agarose beads (Sigma-Aldrich) were added to each reaction. The binding protein was analyzed by Western blot assay.

Cell proliferation and soft agar colony formation

A WST-1 Assay Kit (Roche) was used for cell proliferation assay. Cells were seeded in a 48-well plate and then incubated at 37 °C. Cell numbers were assessed with the WST-1 Assay Kit. For soft agar colony formation, cells were split into the suspension of a single-cell, and then seeded in a media containing 0.4% top layer agar and 0.8% bottom layer agar in a 6-well plate. Cell culture media was changed every 4 days after seeding. Colonies were fixed with 4% paraformaldehyde and stained with 2% crystal violet solution after 2–3 weeks, respectively. The visible colony numbers scored and data were analyzed.

Construction of vectors

The cDNA encoding *DANCR*, *PIK3CA*, *GSK3β*, *RXRA* were amplified from MCF10A cells and sequenced, and then subcloned into the pcDNA3 vector (Invitrogen), subsequently named pCDNA3-*DANCR*, pCDNA3-*PIK3CA*, pCDNA3-*GSK3β*, pCDNA3-*RXRA*. pLVX-*DANCR*, pLVX-*PIK3CA*, pLVX-*GSK3β*, and pLVX-*RXRA* was generated from pCDNA3-*DANCR*, pCDNA3-*PIK3CA*, pCDNA3-*GSK3β*, pCDNA3-*RXRA*, respectively. *PIK3CA* promoter was PCR-amplified from MCF10A cells and sequenced, and then subcloned into pGL3 vector (Promega). A Quik Change Site-Directed Mutagenesis Kit (Stratagene) was used for point mutations. shRNAs for *DANCR* were designed (shDANCR-1 target sequence: 5'-GGAGCTAG AGCAGTGACAAT G-3'; shDANCR-2 target sequence 5'-GGTCACCAGAC TTGCT ACACC-3'), and *RXRA* (shRXRA target sequence: 5'-GGCAAGCACTATGG AGTGTAC-3', respectively).

Tumorigenesis studies

BALB/c-nude mice female at an age of 4–5 weeks (SLAC, Shanghai, China) were randomly divided into 4 per group, and then MDA-MB-231 cells (3×10^6) were implanted subcutaneously into mammary fat pads of each mice. All animal experiments procedures were approved by Zhejiang Provincial People's Hospital the Guidance of Institutional Animal Care and Use Committee (IACUC). The IVIS Lumina imaging station (Caliper Life Sciences) was used for bioluminescence imaging. Different

investigators independently performed mice allocation, surgery and the outcome assessing.

Statistical analysis

All statistical analyses were performed using the GraphPad Prism version 5.0. The significance of the data from patient specimens was determined by Pearson's correlation coefficient. The significance of data from the vitro and vivo between experimental groups was determined by the Student's test or Mann–Whitney *U*-test **P* < 0.05 was considered statistically significant.

Results

Expression of *DANCR* in clinical TNBC specimens


We examined *DANCR* expression using clinical samples consisting of TNBC tissues and normal breast tissues. *DANCR* was found to be significantly upregulated in TNBC tumor tissues compared with that in normal breast tissues (Fig. 1a). To support our finding, we downloaded the TCGA RNA-seq dataset and microarray dataset of invasive breast cancer specimens, respectively. In these datasets, There was a clear trend that the TNBC tissues exhibits higher *DANCR* expression compared to the paired peritumoral tissues (Fig. 1e and Supplementary Figure 1A). Interestingly, higher level of *DANCR* was demonstrated to be associated with bigger tumor size (Fig. 1b). We then detected *DANCR* expression in breast cancer samples of various subtypes. *DANCR* showed significantly higher expression level in TNBC than that in the other subtypes of breast cancer (Fig. 1c). Furthermore, patients with high *DANCR* expression (*n* = 30) suffered poorer overall survival (OS) as compared to low expression group (*n* = 30) (Fig. 1d). Similarly, TCGA microarray dataset also demonstrated the result (Supplementary Figure 1B). Gene amplifications in *DANCR* were observed in mRNA overexpression (TCGA database from cBioPortal) (Supplementary Figure 1C). Taken together, this data demonstrated that *DANCR* is amplified and over-expressed in TNBC tumors.

DANCR inhibition suppressed cell proliferation and tumor growth in TNBC

To further demonstrate the involvement of *DANCR* in TNBC, we tested *DANCR* expression in six breast cancer cell lines (BT549, MCF7, T47D, MDA-MB-231, MDA-MB-453, and MDA-MB-468) and a normal mammary epithelial cell line (MCF10A). *DANCR* expression was markedly upregulated in breast cancer cell lines as compared to that in MCF10A cell lines (Fig. 2a). Importantly, among all the six cancer cell lines, *DANCR* exhibited highest expression levels in two TNBC cell lines (MDA-MB-231 and MDA-MB-468).

We then tested the effect of *DANCR* inhibition on TNBC cell growth. Here, we knocked down the *DANCR*

DANCR → tumor malignancy




expression through treating MDA-MB-231 and MDA-MB-468 cells with the short hairpin RNA-mediated *DANCR* silencing (shRNA) or non-silencing control (shC), and found that depletion of endogenous *DANCR* significantly suppressed cell proliferation in both TNBC cell lines compared with the controls (Fig. 2b, c). Moreover, *DANCR* knockdown also impaired soft agar colony formation in MDA-MB-231 and MDA-MB-468 cells (Fig. 2d, e).

To further elucidate the TNBC tumorigenesis with *DANCR*, analysis of the orthotopic breast cancer model was performed. MDA-MB-231 cell lines transduced with shDANCR-1, shDANCR-2 or shControl (shC) were separately injected into the mice mammary gland fat pads. Remarkably, knockdown of *DANCR* was significantly decreased TNBC tumor growth compared with controls (Fig. 2f, g). These data suggested that *DANCR* contributes to TNBC cell proliferation and tumor growth.

DANCR interacts with RXRA in TNBC cells

Recent studies have demonstrated that lncRNAs mainly function as sponges to bind functional proteins and then influence their downstream genes expression^{23–25}. Thus, We hypothesized that *DANCR*-regulated tumorigenesis depends on its binding proteins. *DANCR* was examined for transcription factor binding sites using a JASPAR database of transcription factor binding profiles, which identified two RXRA-binding sites as the most potential candidates. It is predicted that RXRA may bind with *DANCR* at both 211 to 225 and 269 to 283 sites (Fig. 3a). To test this, we performed RIP quantitative PCR with an antibody against RXRA from nuclear extracts of both MDA-MB-231 and MDA-MB-468 cells. We demonstrated that *DANCR* specifically bound to endogenous RXRA protein (Fig. 3b).

We next constructed *DANCR* plasmids containing a wild type and three mutant types including *DANCR*-




RXRA binding site1 (Mut1), site2 (Mut2), or both sites (Mut1/2). As we predicted, re-expression of shRNA-resistant *DANCR* cDNA encoding the wild type restored the binding of *DANCR* with RXRA, whereas re-expression of a *DANCR* shRNA-resistant plasmid containing the *DANCR*-RXRA binding site1, site 2, or two sites mutants did not rescue it, suggesting that these two sites are critical for *DANCR*-RXRA binding (Fig. 3c, d).

To further validate the binding between *DANCR* and RXRA, we performed RNA pull-down (Fig. 3e), and deletion-mapping methods (Fig. 3f, g) to demonstrate whether RXRA would bind within specific regions of *DANCR*. These data identified a 300nt region at the 5' end of *DANCR* required for the binding with RXRA (Fig. 3g). Taken together, the RIP, RNA pull-down, and deletion-mapping data validate a specific binding between RXRA and *DANCR*.

JASPAR predicts RXRA binding on *DANCR*

shRNA → *DANCR* + RXRA → proliferation





DANCR regulates RXRA phosphorylation

To explore the role of RXRA in *DANCR*-mediated TNBC tumor growth, we first assessed RXRA protein and expression in *DANCR* depletion TNBC cells. We found that *DANCR* knockdown did not affect the protein level of RXRA in MDA-MB-231 and MDA-MB-468 cells (Fig. 4a). Moreover, *DANCR* depletion had no effect on RXRA mRNA level (Fig. 4b). However, Western blot analysis showed that lower phosphorylation level of RXRA was found in the *DANCR*-knockdown group as compared to that of the controls (Fig. 4c). Furthermore, re-expression of shRNA resistant *DANCR* wild type rescued *DANCR* knockdown-inhibited RXRA phosphorylation, whereas re-expression of shRNA resistant *DANCR* mutant type of the RXRA binding did not affect it (Fig. 4d). Together, Our data suggest that *DANCR* enhance RXRA protein phosphorylation in TNBC.

DANCR facilitates PIK3CA transcription in a RXRA-mediated manner

Since PI3K signaling is critical for TNBC proliferation and Akt is a dominant downstream effector of PI3K signaling pathway²⁶, we explored the effects of *DANCR* depletion on expression of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in MDA-MB-231 and MDA-MB-468 cells. As shown in Fig. 5a, b, knockdown of *DANCR* significantly inhibited PIK3CA protein and mRNA expression levels in both TNBC cells. However, knockdown of RXRA significantly rescued *DANCR* depletion-inhibited PIK3CA expression (Fig. 5c). These data suggest that *DANCR* may mediate RXRA to regulate PIK3CA expression.

To validate that RXRA regulates PIK3CA expression in TNBC cells, we predicted RXRA-binding sites to the promoter of PIK3CA using the JASPAR database of




transcription factor binding profiles. One RXRA binding site was detected in the promoter of PIK3CA at the –1148 to –1134 site (Fig. 5d). RXRA Knockdown increased PIK3CA mRNA levels by qRT-PCR assays (Supplementary Figure 3). CHIP-qPCR assays using the antibody against RXRA demonstrated that RXRA bind to PIK3CA promoter (Fig. 5e). Promoter luciferase assays further validated that RXRA overexpression markedly decreased PIK3CA promoter transcriptional activity compared with the control, whereas the transcriptional activity was definitely restored after the mutation of RXRA binding site in PIK3CA promoter (Fig. 5f). Taken together, these data indicate that RXRA acts as a transcription repressors to inhibit PIK3CA expression.

To validate that *DANCR*/RXRA/PIK3CA signaling pathway regulates TNBC tumor growth, we down-regulated RXRA and overexpressed PIK3CA in MDA-MB-231 and MDA-MB-468 cells with a RXRA shRNA or a PIK3CA vector (Fig. 5g and Supplementary Figure 2A). Knockdown of RXRA rescued *DANCR* depletion-inhibited PIK3CA and Akt phosphorylation (Fig. 5g and Supplementary Figure 2A), cell proliferation (Fig. 5h and Supplementary Figure 2B), colony formation (Fig. 5i and Supplementary Figure 2C). Moreover, overexpression of PIK3CA restored Akt phosphorylation (Fig. 5g and Supplementary Figure 2A), cell proliferation (Fig. 5h and Supplementary Figure 2B), colony formation (Fig. 5i and Supplementary Figure 2C) inhibited by *DANCR* knockdown. Furthermore, *DANCR* expression was found to be correlated with PIK3CA expression (Supplementary

Figure 2D). These data further demonstrate that *DANCR* mediates RXRA to upregulate PIK3CA expression, resulting in enhancing PI3K/AKT signaling pathway and promoting TNBC tumor growth.

***DANCR*-mediated RXRA phosphorylation depends on GSK3 β**



Since the glycogen synthase kinase 3 beta (GSK3 β) had been reported to promote RXRA phosphorylation in colorectal cancer cells²⁷, we detected whether *DANCR*-regulated RXRA phosphorylation depends on GSK3 β . As shown in Fig. 6a, compared with the control group, overexpression of *DANCR* increased RXRA binding with GSK3 β , RXRA phosphorylation, Akt phosphorylation and PIK3CA expression in both TNBC cells (Fig. 6a). Knockdown of *DANCR* decreased RXRA binding with GSK3 β , RXRA phosphorylation, Akt phosphorylation and PIK3CA expression in both TNBC cells (Fig. 6b). Furthermore, overexpression of GSK3 β increased RXRA phosphorylation, Akt phosphorylation and PIK3CA expression (Fig. 6c) inhibited by *DANCR* knockdown. Consistent with previous study²⁷, overexpression of RXRA increased its binding with GSK3 β and decreased Akt phosphorylation and PIK3CA expression in MDA-MB-231 and MDA-MB-468 cells (Fig. 6d). Overexpression of RXRA significantly restored GSK3 β association and Akt phosphorylation and PIK3CA expression inhibited by *DANCR* knockdown (Fig. 6d). These data support that *DANCR* depends on GSK3 β to mediate RXRA phosphorylation in both TNBC cells.



Ser49/Ser78 sites of *RXRA* protein are critical for *DANCR*-mediated TNBC tumor growth

Since the roles of *RXRA* phosphorylation mediated by *DANCR* in TNBC is not well understood, we focused on the role of *RXRA* phosphorylation in *DANCR*-regulated TNBC cell proliferation. To detect whether *RXRA* phosphorylation is necessary to activate PI3K/AKT signaling pathway, we generated the GSK3 β kinase deficient mutant plasmid, GSK3 β -K58A. As shown Fig. 7a, overexpression of GSK3 β cDNA encoding the wild type restored *DANCR* knockdown-inhibited *RXRA* phosphorylation, Akt phosphorylation and *PIK3CA* expression, whereas transfection of GSK3 β kinase deficient mutant type did not rescue it. Next, we predicted

potential serine phosphorylation sites of the *RXRA* protein using the Phosphor Motif Finder Program. Two serine phosphorylation candidate sites at Ser49 and Ser78 were identified. Transfection of *RXRA* wild type in MDA-MB-231 cells restored its binding with GSK3 β inhibited by *DANCR* knockdown, and further decreased *DANCR* depletion-inhibited Akt phosphorylation, *PIK3CA* expression, cell proliferation, and soft agar colony formation (Fig. 7b–e). However, transfection of *RXRA*^{S49A/S78A} mutant did not rescued it compared with the wild type group (Fig. 7b–e). Taken together, these data demonstrates that serine phosphorylation of *RXRA* plays a crucial role in activating the PI3K/AKT signaling pathway.





Discussion

In this study, we demonstrated a new mechanism by which *DANCR*-upregulated PI3K/AKT signaling pathway through activating serine phosphorylation of RXRA protein is important for TNBC cell proliferation and tumor growth (Fig. 8). By means of facilitating connection between RXRA and GSK3 β , *DANCR* promotes the phosphorylation of RXRA, leading to suppress RXRA induced inhibition of PIK3CA transcription, thereby activating PI3K/AKT downstream signaling and ultimately promoting TNBC tumorigenesis.

Our data demonstrate that *DANCR* promotes TNBC tumorigenesis. *DANCR* was previously identified to play an important role in maintaining the undifferentiated cell state^{15,16}. Previous work demonstrated that *DANCR*

interacts with EZH2 to form a complex to promote stem cell characteristics^{16,28}. It has been well documented that *DANCR* was overexpressed and amplified in breast cancer, and knockdown of *DANCR* significantly inhibited cell proliferation and invasion in breast cancer through facilitating binding of EZH2 to the promoters of ABCG2 and CD44 genes¹⁴. Here, we report that *DANCR* is upregulated in clinical TNBC samples, and higher *DANCR* level is positively correlated with poorer prognosis of TNBC patients. Knockdown of *DANCR* significantly inhibited TNBC cell proliferation, colony formation in vitro, and tumor growth in vivo. These results strongly support that *DANCR* is critical for TNBC tumorigenesis.

Our results also demonstrate that *DANCR* mediates TNBC through RXRA. RXRA had been reported to play



critical roles in breast cancer cell progression^{29,30}. Phosphorylation of the RXRA at serine 260 decreases its coactivator recruitment ability, leading to inhibition of RXRA transcriptional activity and enhanced cancer cell proliferation^{31,32}. *DANCR* has also been identified as a molecular sponge mediating miR-758-3p¹⁷ and miR-577¹⁸ in non-small cell lung cancer and colorectal cancer, respectively. Furthermore, some studies showed that *DANCR* regulate breast cancer through binding and phosphorylating EZH2²⁵. In this study, our data showed that *DANCR* directly bound with RXRA and mediated its phosphorylation. Knockdown of *DANCR* enhanced RXRA phosphorylation. Re-expression of shRNA resistant *DANCR* wild type impaired *DANCR* knockdown-promoted RXRA phosphorylation, whereas re-expression of shRNA resistant mutant type of the *DANCR*-RXRA binding did not affect it. Knockdown of RXRA rescued *DANCR* depletion-inhibited cell proliferation and soft

agar colony formation. Taken together, our data demonstrate that *DANCR* regulate TNBC cell proliferation through RXRA phosphorylation.

Our results further suggest that *DANCR* mediates TNBC through RXRA- downregulating PI3K/AKT signaling pathway. Activating PI3K/AKT signaling was reported to be associated with poor OS in patients with breast cancer³³. PIK3CA activation was also demonstrated to be critical for enhancing PI3K/AKT signaling²². RXRA was reported to mediate PI3K/AKT signaling in response to stem cell differentiation and provoke tumor suppression³⁴. Inhibition of the N-terminally truncated RXRA association with the PI3K p85α subunit also resulted in suppression of PI3K/AKT signaling activation³⁵. Here, we found that RXRA binds with the promoter of PIK3CA and downregulate PIK3CA transcription. We also observed that knockdown of *DANCR* inhibited RXRA protein phosphorylation and PIK3CA expression level.




Fig. 8 A working model for *DANCR*-mediated TNBC

tumorigenesis. *DANCR* interacts with *RXRA*, and highly promotes *GSK3β* phosphorylating *RXRA*, and inhibits *RXRA* binding with *PIK3CA* promoter to upregulate its transcription, resulting in activating *PI3K/AKT* signaling pathway and TNBC tumorigenesis

Author details

¹Department of Radiation Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China. ²Department of Thyroid and Breast Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China. ³Department of Oncology, Taixing People's Hospital, Taixing, Jiangsu 225300, P.R. China. ⁴Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China. ⁵Department of Orthopaedic Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China. ⁶Department of The Otolaryngology, Meizhou People's Hospital, Meizhou, Guangdong 514000, P.R. China. ⁷Department of Cardiology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (<https://doi.org/10.1038/s41419-018-1220-7>).

Received: 12 October 2018 Revised: 1 November 2018 Accepted: 14 November 2018

Published online: 05 December 2018

References

- Desantis, C., Ma, J., Bryan, L. & Jemal, A. Breast cancer statistics, 2013. *CA Cancer J. Clin.* **64**, 52–62 (2014).
- Donepudi, M. S., Kondapalli, K., Amos, S. J. & Venkateshan, P. Breast cancer statistics and markers. *J. Cancer Res. Ther.* **10**, 506 (2014).
- Weigelt, B., Eberle, C., Cowell, C. F., Ng, C. K. & Reisfilho, J. S. Metaplastic breast carcinoma: more than a special type. *Nat. Rev. Cancer* **14**, 147–148 (2014).
- Denkert, C., Liedtke, C., Tutt, A. & Von, M. G. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. *Lancet* **389**, 2430 (2016).
- Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nat. Rev. Clin. Oncol.* **13**, 674 (2016).
- Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J. Clin. Invest.* **121**, 2750 (2011).
- Li, W. et al. The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. *J. Clin. Invest.* **127**, 3421–3440 (2017).
- Zhou, W. et al. The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. *Sci. Signal.* **10**, 483 (2017).
- Lin, A. et al. The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. *Nat. Cell Biol.* **19**, 238–251 (2017).
- Liu, Y., Zhang, M., Liang, L., Li, J. & Chen, Y. X. Over-expression of lncRNA *DANCR* is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer. *Int. J. Clin. Exp. Pathol.* **8**, 11480 (2015).
- Shi, H. et al. Long non-coding RNA *DANCR* promotes cell proliferation, migration, invasion and resistance to apoptosis in esophageal cancer. *J. Thorac. Dis.* **10**, 2573 (2018).
- Yuan, S. X. et al. Long noncoding RNA *DANCR* increases stemness features of hepatocellular carcinoma via de-repression of *CTNBN1*. *Hepatology* **63**, 499–511 (2016).
- Jiang, N. et al. lncRNA *DANCR* promotes tumor progression and cancer stemness features in osteosarcoma by upregulating *AXL* via miR-33a-5p inhibition. *Cancer Lett.* **405**, 46–55 (2017).

Acknowledgements

This study was supported in part by grants from the Zhejiang Provincial Nature Science Foundation of China (Grant number: LY18H160035 to Xiaodong Liang).

14. Sha, S., Yuan, D., Liu, Y., Han, B. & Zhong, N. Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression. *Biol. Open* **6**, 1310–1316 (2017).
15. Kretz, M. et al. Suppression of progenitor differentiation requires the long noncoding RNA ANCR. *Genes Dev.* **26**, 338 (2012).
16. Zhu, L. & Xu, P. C. Downregulated LncRNA-ANCR promotes osteoblast differentiation by targeting EZH2 and regulating Runx2 expression. *Biochem. Biophys. Res. Commun.* **432**, 612–617 (2013).
17. Wang, S. & Jiang, M. The long non-coding RNA-DANCR exerts oncogenic functions in non-small cell lung cancer via miR-758-3p. *Biomed. Pharmacother.* **103**, 94–100 (2018).
18. Wang, Y. et al. Long noncoding RNA DANCR promotes colorectal cancer proliferation and metastasis via miR-577 sponging. *Exp. Mol. Med.* **50**: 57 (2018).
19. Jia, J. et al. Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3. *Oncotarget* **7**, 37868–37881 (2016).
20. Lu, Y. et al. MYC targeted long noncoding RNA DANCR promotes cancer in part by reducing p21 levels. *Cancer Res.* **78**, 64–74 (2018).
21. Hao, Y. P., Qiu, J. H., Zhang, D. B. & Yu, C. G. Long non-coding RNA DANCR, a prognostic indicator, promotes cell growth and tumorigenicity in gastric cancer. *Tumour Biol.* **39**, 1010428317699798 (2017).
22. Tang, J., Zhong, G., Wu, J., Chen, H. & Jia, Y. SOX2 recruits KLF4 to regulate nasopharyngeal carcinoma proliferation via PI3K/AKT signaling. *Oncogenesis* **7**, 61 (2018).
23. Xu, M. D. et al. A positive feedback loop of lncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and invasion. *Clin. Cancer Res.* **23**, 2071 (2016).
24. Wilusz, J. E., Sunwoo, H. & Spector, D. L. Long noncoding RNAs: functional surprises from the RNA world. *Genes Dev.* **23**, 1494–1504 (2009).
25. Z, L. et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. *Cell Death Differ.* **24**, 59 (2016).
26. Hatem, R. et al. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. *Oncotarget* **7**, 48206–48219 (2016).
27. Liang, J. et al. miR-27a-3p targeting RXRa promotes colorectal cancer progression by activating Wnt/ β -catenin pathway. *Oncotarget* **8**, 82991–83008 (2017).
28. Jia, Q., Jiang, W. & Ni, L. Down-regulated non-coding RNA (lncRNA-ANCR) promotes osteogenic differentiation of periodontal ligament stem cells. *Arch. Oral Biol.* **60**, 234–241 (2015).
29. Peng, X., Yun, D. & Christov, K. Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids. *Int. J. Oncol.* **25**, 961–971 (2004).
30. Sun, S. Y. & Lotan, R. Retinoids and their receptors in cancer development and chemoprevention. *Crit. Rev. Oncol. Hematol.* **41**, 41–55 (2002).
31. Matsushima-Nishiwaki, R. et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. *Cancer Res.* **61**, 7675 (2001).
32. Macoritto, M. et al. Phosphorylation of the human retinoid X receptor alpha at serine 260 impairs coactivator(s) recruitment and induces hormone resistance to multiple ligands. *J. Biol. Chem.* **283**, 4943–4956 (2008).
33. Qiu, Z., Li, Y., Zeng, B., Guan, X. & Li, H. Downregulated CDKN1C/p57kip2 drives tumorigenesis and associates with poor overall survival in breast cancer. *Biochem. Biophys. Res. Commun.* **497**, 187 (2018).
34. Zhang, R. et al. RXRa provokes tumor suppression through p53/p21/p16 and PI3K-AKT signaling pathways during stem cell differentiation and in cancer cells. *Cell Death Dis.* **9**, 532 (2018).
35. Chen, L. et al. Sulindac-derived RXRa modulators inhibit cancer cell growth by binding to a novel site. *Chem. Biol.* **21**, 596–607 (2014).